ArticleThe oncologist2020
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Margaret E Gatti-Mays et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this papertrialcites it